KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Net Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Net Margin for 11 consecutive years, with 867.29% as the latest value for Q1 2025.

  • Quarterly Net Margin changed N/A to 867.29% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 4694.41% through Dec 2025, changed N/A year-over-year, with the annual reading at 4694.41% for FY2025, N/A changed from the prior year.
  • Net Margin for Q1 2025 was 867.29% at Xenon Pharmaceuticals, up from 28143.94% in the prior quarter.
  • The five-year high for Net Margin was 220.98% in Q1 2022, with the low at 28143.94% in Q3 2022.
  • Average Net Margin over 3 years is 4672.1%, with a median of 769.17% recorded in 2021.
  • Peak annual rise in Net Margin hit 13104bps in 2022, while the deepest fall reached -2780876bps in 2022.
  • Over 3 years, Net Margin stood at 671.05% in 2021, then plummeted by -4094bps to 28143.94% in 2022, then soared by 97bps to 867.29% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 867.29%, 28143.94%, and 5813.06% for Q1 2025, Q3 2022, and Q2 2022 respectively.